Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease

Multiple Sclerosis

Volumn 21, Issue 7, 2015, Pages 866-874

  Höftberger, Romana ^a,b   Sepulveda, María ^a   Armangue, Thaís ^a   Blanco, Yolanda ^a   Rostásy, Kevin ^a,c,d   Cobo Calvo, Alvaro ^e   Olascoaga, Javier ^f   Ramió Torrentà, Lluís ^g   Reindl, Markus ^c   Benito León, Julián ^h   Casanova, Bonaventura ⁱ   Arrambide, Georgina ^j   Sabater, Lidia ^a   Graus, Francesc ^a   Dalmau, Josep ^a,k   Saiz, Albert ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL DONOSTIA   (Spain)

^g HOSPITAL JOSEP TRUETA   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

antibodies to myelin oligodendrocyte glycoprotein; aquaporin 4 antibody; longitudinally extensive myelitis; Neuromyelitis optica; optic neuritis

Indexed keywords

AQUAPORIN 4 ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; AUTOANTIBODY; AUTOANTIGEN; MOG PROTEIN, HUMAN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADULT; AGED; ANTIBODY TITER; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINALLY EXTENSIVE MYELITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; PHENOTYPE; RETROSPECTIVE STUDY; ADOLESCENT; BLOOD; IMMUNOLOGY; ONSET AGE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; AQUAPORIN 4; AUTOANTIBODIES; AUTOANTIGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA; YOUNG ADULT;

EID: 84930411790     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514555785     Document Type: Article

References (25)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6: 805-815
2. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012; 78: 665-671
3. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013; 81: 1197-1204
4. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology. 2013; 80: 2194-2200
5. Reindl M, Di Pauli F, Rostasy K, et al. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013; 9: 455-461
6. Pröbstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011; 77: 580-588
7. Di Pauli F, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol. 2011; 138: 247-254
8. Rostásy K, Reindl M.. Role of autoantibodies in acquired inflammatory demyelinating diseases of the central nervous system in children. Neuropediatrics. 2013; 44: 297-301
9. Rostásy K, Mader S, Hennes E, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler. 2013; 19: 1052-1059
10. Rostásy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol. 2012; 69: 752-756
11. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol. 2014; 71: 276-283
12. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011; 8: 184
13. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014; 82: 474-481
14. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999; 53: 1107-1114
15. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66: 1485-1489
16. Sepulveda M, Blanco Y, Rovira A, et al. Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Mult Scler. 2013; 19: 742-748
17. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010; 17: 1019-1032
18. Blanco Y, Hankiewicz K, Llufriu S, et al. Clinical spectrum associated with aquaporin-4 antibodies (NMO-IgG). Neurologia. 2010; 25: 5-12
19. Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: Revisions to the 2007 definitions. Mult Scler. 2013; 19: 1261-1267
20. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50: 121-127
21. Höftberger R, Sabater L, Marignier R, et al. An optimized immunohistochemistry technique improves NMO-IgG detection: Study comparison with cell-based assays. PLoS One. 2013; 8: e79083
22. Titulaer M, Höftberger R, Izuka T, et al. Overlapping demyelinating syndromes and anti-NMDA receptor encephalitis. Ann Neurol. 2014; 75: 411-428
23. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: Diagnostic clues for this association. Brain. 2008; 131: 2553-2563
24. Kitley J, Leite MI, Kuker W, et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol. 2013; 70: 1375-1381
25. Jiao Y, Fryer JP, Lennon VA, et al. Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol. 2014; 71: 48-54